Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px
Document › Details

Evotec AG. (12/22/14). "Press Release: Evotec and Ohio State to Collaborate on Novel Cancer Therapy". Hamburg.

Organisations Organisation Evotec AG (FSE: EVT, TecDAX)
  Group Evotec (Group)
  Organisation 2 Ohio State University, Comprehensive Cancer Center
  Group Ohio State University
Products Product drug discovery
  Product 2 cancer drug
Person Person Lanthaler, Werner (Evotec AG 200903– CEO before Intercell AG CFO before Austrian Industrial Assoc before McKinsey)
     


*Collaboration leverages the breadth & experience of Evotec's drug discovery infrastructure
*Efforts will explore the use of a novel approach, discovered at Ohio State, for targeting mutant KRas

Hamburg, Germany - 22 December 2014: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced a research collaboration with the laboratories of Prof. Roger Briesewitz at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute ("OSUCCC - James").

The objective of the collaboration is to progress a novel mechanism for engaging the KRas target discovered at The Ohio State University using Evotec's technology platform and broad expertise in drug discovery and pre-clinical development, thereby validating and progressing novel leads into pharmaceutically developable candidates.

KRas is a small GTPase regulating the RAS/MAPK signalling cascade that governs cell division. Mutations in KRas are early transforming events in tumourigenesis and are highly prevalent in lethal cancers such as lung, colon and pancreatic cancer. Addressing the challenging tractability of this well-established oncology target, work conducted at Ohio State provides a novel route to engage the target.

"Working and initiating a strategic dialogue with OSUCCC is a great privilege for us, especially in such an important field in oncology. Activating mutations of KRas are one of the most frequent genetic events in cancers, and yet mutant KRas has long been considered an intractable drug target. However, working with Roger and his team, we believe we have an opportunity to attack this elusive target from a different angle with the potential to deliver an exciting new anti-cancer therapeutic", said Dr Werner Lanthaler, Chief Executive Officer of Evotec.

"Through this collaboration with Evotec, novel biological discoveries and medical insights made at Ohio State will be effectively translated into a state-of-the-art drug discovery project. The collaboration is already demonstrating the benefit of an alliance in accelerating drug discovery projects", said Dr Tim Wright, Founding Partner and Director Drug Development Institute OSU Comprehensive Cancer Center James Cancer Hospital & Solove Research Institute, Vice President, Technology Commercialization Office.


ABOUT THE OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER - ARTHUR G. JAMES CANCER HOSPITAL AND RICHARD J. SOLOVE RESEARCH INSTITUTE
Ohio State's Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute ("OSUCCC - James") strives to create a cancer-free world by integrating molecular- and genetic-based discoveries into patient care, a strategy that leads to better prevention, detection and treatment of individual cancers. OSUCCC - James is one of only 41 National Cancer Institute-designated Comprehensive Cancer Centers and one of only four centers funded by the NCI to conduct both phase I and phase II clinical trials. More than 300 cancer researchers from 12 of Ohio State's 14 colleges collaborate across research programs and disciplines to make some of the world's most game-changing discoveries. In December 2014, The Ohio State University will open the doors of the new James Cancer Hospital and Solove Research Institute, a transformational facility that fosters collaboration and integration of cancer research and clinical cancer care. The new James will help revolutionize cancer prevention and care by enabling world-class oncologists and researchers to work side-by-side to solve the mysteries of this disease.


FORWARD LOOKING STATEMENTS - Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

   
Record changed: 2017-04-02

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Evotec (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px




» top